2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Atherosclerosis D050197 85 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Tibial Fractures D013978 4 associated lipids
Thrombosis D013927 49 associated lipids
Pulmonary Heart Disease D011660 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Endometriosis D004715 29 associated lipids
Down Syndrome D004314 18 associated lipids
Diseases in Twins D004200 4 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Carotid Artery Thrombosis D002341 7 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Body Weight D001835 333 associated lipids
Bartter Syndrome D001477 5 associated lipids
Ascites D001201 25 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Angina, Unstable D000789 14 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Mizugaki M et al. Microdetermination of 2,3-dinor-6-ketoprostaglandin F1 alpha in human urine using gas chromatography-high-resolution selected-ion monitoring. 1994 J. Chromatogr. B, Biomed. Appl. pmid:7952110
Daniel VC et al. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. 1994 J. Chromatogr. B, Biomed. Appl. pmid:8205238
Ylikorkala O et al. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. 1987 J. Clin. Endocrinol. Metab. pmid:2960690
Ylikorkala O et al. Renal prostacyclin and thromboxane in normotensive and preeclamptic pregnant women and their infants. 1986 J. Clin. Endocrinol. Metab. pmid:3536979
Fitzgerald DJ et al. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. 1988 J. Clin. Invest. pmid:3183064
Dowd NP et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. 2001 J. Clin. Invest. pmid:11518732
Song WL et al. Niacin and biosynthesis of PGDâ‚‚by platelet COX-1 in mice and humans. 2012 J. Clin. Invest. pmid:22406532
Neiman J et al. Urinary excretion of 2, 3-dinor-6-keto prostaglandin F1 alpha and platelet thromboxane formation during ethanol withdrawal in alcoholics. 1987 J. Clin. Pathol. pmid:3584500
Kimblad PO et al. Prostanoid release after lung transplantation. 1996 J. Heart Lung Transplant. pmid:8913917
Barden AE et al. Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? 1999 J. Hypertens. pmid:10489109
Rasmanis G et al. Prostacyclin production in myocardial infarction in the acute phase and during follow-up. 1991 J. Intern. Med. pmid:1997639
Morrow JD et al. Increased formation of thromboxane in vivo in humans with mastocytosis. 1999 J. Invest. Dermatol. pmid:10417625
Mastrogiannis DS et al. Cocaine decreases urinary prostacyclin release in pregnancy: correlation with uterine and umbilical Doppler velocimetry. 2003 J. Matern. Fetal. Neonatal. Med. pmid:15061316
Kuehl PG et al. Systemic production of prostacyclin and thromboxane A2 does not correlate with patency of the ductus arteriosus in very low birth weight infants. 1986 J. Pediatr. pmid:3519915
Brown NJ et al. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. 1996 J. Pharmacol. Exp. Ther. pmid:8930174
Catella-Lawson F et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. 1999 J. Pharmacol. Exp. Ther. pmid:10215647
Capone ML et al. Human pharmacology of naproxen sodium. 2007 J. Pharmacol. Exp. Ther. pmid:17473175
Neiman J et al. Effects of a small dose of ethanol and calcium carbimide-induced acetaldehyde intoxication on human platelet aggregation, associated thromboxane formation and urinary excretion of 2,3-dinor-6-keto prostaglandin F1 alpha. 1987 J. Toxicol. Clin. Toxicol. pmid:3612897
Lin JS et al. The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. 1992 J. Urol. pmid:1635125
Hashimoto K et al. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. 2004 J. Virol. pmid:15367596
Mills JL et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. 1999 JAMA pmid:10432033
Stichtenoth DO et al. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. 2005 Kidney Int. pmid:16221219
Edlund A et al. Myocardial ischaemia triggers formation of thromboxane. 1987 Lancet pmid:2887865
Gréen K et al. Deficient prostacyclin formation after acute myocardial infarction. 1987 Lancet pmid:2883378
Watson ML et al. Systemic prostaglandin I2 synthesis is normal in patients with Bartter's syndrome. 1983 Lancet pmid:6135873
Liggins GC et al. Prostacyclin and maternal lupus anticoagulant. 1984 Lancet pmid:6140483
Tulppala M et al. Thromboxane dominance and prostacyclin deficiency in habitual abortion. 1991 Lancet pmid:1672969
Falardeau P and Brash AR Quantitation of two dinor metabolites of prostacyclin by GC-MS. 1982 Meth. Enzymol. pmid:6752645
Fitzgerald DJ et al. Platelet activation in unstable coronary disease. 1986 N. Engl. J. Med. pmid:3531859
Alessandrini P et al. Thromboxane biosynthesis and platelet function in type I diabetes mellitus. 1988 N. Engl. J. Med. pmid:3292913
Christman BW et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. 1992 N. Engl. J. Med. pmid:1603138
FitzGerald GA et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. 1984 N. Engl. J. Med. pmid:6231483
Knapp HR et al. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. 1986 N. Engl. J. Med. pmid:3007982
Goldberg MR et al. Prostacyclin biosynthesis and platelet function in autonomic dysfunction. 1985 Neurology pmid:3838109
Yuhki K et al. [Prostaglandin I2 and its metabolites]. 2010 Nippon Rinsho pmid:20960743
Ylikorkala O et al. Urinary prostacyclin and thromboxane metabolites in drinking pregnant women and in their infants: relations to the fetal alcohol effects. 1988 Obstet Gynecol pmid:3275910
Rauramo I et al. Prostacyclin and thromboxane in pregnant and nonpregnant women in response to exercise. 1995 Obstet Gynecol pmid:7770249
Saareks V et al. Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. 2002 Pharmacol. Toxicol. pmid:12403056
McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874808
Praticò D et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11248083
Förstermann U et al. An increase in the ratio of thromboxane A2 to prostacyclin in association with increased blood pressure in patients on cyclosporine A. 1989 Prostaglandins pmid:2662262
Balazy M et al. Facile method for preparation of 2,3-dinor-6-keto PGF1 alpha, the major urinary metabolite of prostacyclin. 1988 Prostaglandins pmid:3070630
Falardeau P et al. Urinary levels of 2,3-dinor-6-oxo-PGF1 alpha: a reliable index of the production of PGI2 in the spontaneously hypertensive rat. 1985 Prostaglandins pmid:3890022
Riutta A et al. Adrenaline infusion increases systemic prostacyclin production in man. 1994 Prostaglandins pmid:7972879
Rasmanis G et al. Implications of the prognostic importance of exercise-induced thromboxane formation in survivors of an acute myocardial infarction. 1995 Prostaglandins pmid:7667506
Vernon WB Prostaglandins and pancreas transplantation. 1991 Prostaglandins pmid:2052737
Farker K et al. Measurements of urinary prostaglandins in young ovulatory women during the menstrual cycle and in postmenopausal women. 1997 Prostaglandins pmid:9373880
Hotter G et al. Altered levels of tissue and urinary prostacyclin in rats subjected to pancreas transplantation. 1991 Prostaglandins pmid:2052738
Ylikorkala O et al. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. 1990 Prostaglandins pmid:2106714
Henriksson P et al. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo. 1990 Prostaglandins pmid:2106716